Sign in to tag this notice and share notes on it with your team.
Winston AI writes a plain-English brief of every opportunity — what the buyer wants, and what affects whether to bid. It's free in every Scout workspace. Sign in to see it.
NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731
Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
| Lot | Title | Value |
|---|---|---|
| 1 | Lot 1 | — |
| 2 | Lot 2 | — |
| Title | Supplier | Value | Awarded |
|---|---|---|---|
| Lot 1 - CM/PHR/25/5731/01 – NHS Branded Medicines Tranche B for London & South of England. | Amgen Ltd | £813,863,584 | 31 May 2026 |
| Lot 2 -CM/PHR/25/5731/02 – NHS Branded Medicines for Ustekinumab for North of England and Midlands & East | THORNTON & ROSS LIMITED | £18,903,212 | 31 May 2026 |